NCT02571738TerminatedPhase 3
A Multicenter, Randomized, Single-Blind Study With an Open-Label Extension Option to Further Evaluate the Safety and Efficacy of Cryopreserved Human Amniotic Membrane for the Treatment of Chronic Diabetic Foot Ulcers
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 3
- Status
- Terminated
- Sponsor
- Osiris Therapeutics
- Enrollment
- 108
- Locations
- 18
- Primary Endpoint
- Complete closure of the index wound, defined as 100% re-epithelialization as determined by the Investigator, by the End of Single-Blind Treatment Visit with follow-up confirmation of continued closure at 2 consecutive study visits 2 weeks apart
Study Overview
Brief Summary
A Multicenter, Randomized, Single-Blind Study with an Open-Label Extension Option to Further Evaluate the Safety and Efficacy of Cryopreserved Human Amniotic Membrane for the Treatment of Chronic Diabetic Foot Ulcers
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Between 18 years and 80 years of age inclusive, as of the date of screening
- •Confirmed diagnosis of Type I or Type II Diabetes
- •An Index Ulcer defined as chronic (presence of wound for > 4 weeks), but not present for more than 52 weeks at the Screening Visit
- •Index Ulcer is located below the malleoli on the plantar or dorsal surface of the foot
- •The Index Ulcer is between 1 cm2 and 15 cm2, inclusive, at the Screening Visit
- •The Index Ulcer extends into the dermis or subcutaneous tissue without evidence of exposed muscle, tendon, bone, or joint capsule
- •Wound is free of necrotic debris
- •Patient has adequate circulation to the foot as documented by either:
- •Ankle Brachial Index (ABI) > 0.70 and < 1.30, or
- •In patients with non-compressible ankle vessels defined as an ABI ≥ 1.30, a Toe Brachial Index (TBI) ≥ 0.50, or
- •In patients with non-compressible ankle vessels defined as an ABI ≥ 1.30 and TBI cannot be performed (e.g., toe is absent, wounds are present, or site cannot perform a TBI), a Doppler waveform in the posterior tibial or dorsalis pedis arteries at the ankle consistent with adequate flow in the foot (biphasic or triphasic) and other diagnostic confirmation of adequate flow (e.g., duplex imaging, normal pulse volume recording [PVR] testing).
Exclusion Criteria
- •Index Ulcer is of non-diabetic pathophysiology
- •Gangrene is present on any part of the affected foot
- •Index Ulcer is over an active Charcot deformity
- •The longest dimension of the Index Ulcer exceeds 5 cm at the Baseline Visit
- •Patient is currently receiving dialysis or planning to go on dialysis
- •Patient has had 2 or more previous disease-related amputations of the lower extremities
- •Patient has a glycated hemoglobin A1c (HbA1c) level of >10%
- •Chronic oral steroid use >7.5 mg daily for longer than 3 months at the time of screening
- •Patient is receiving IV corticosteroids, immunosuppressive or cytotoxic agents at the time of screening
- •Requiring intravenous (IV) antibiotics to treat the index wound infection at the time of screening
- •Patient has an ulcer within 5 cm of the Index Ulcer identified for study consideration
- •Patient is Human Immunodeficiency Virus (HIV) positive or has Acquired Immune Deficiency Syndrome (AIDS)
- •Current evidence of cellulitis, or other evidence of infection including fever or pus drainage from the wound site
- •Current evidence of osteomyelitis or history of osteomyelitis within 30 days of screening
- •Patient has active malignancy other than non-melanoma skin cancer
- •Patient's Index Ulcer has decreased by ≥20% during 1-week screening period
- •Patient's random blood sugar is >350 mg/dl at screening
- •Patient has untreated alcohol or substance abuse at the time of screening
- •Pregnant women and women who are breastfeeding
- •Patient is currently enrolled or participated in another investigational device, drug, or biological trial within 30 days of screening
- •Patient has had within the last 30 days, or is currently undergoing, or is planning for wound treatments with growth factors, living skin, dermal substitutes or other advanced biological therapies
- •Patient is an employee, or an immediate family member of an employee, of the sponsor company or site research staff conducting the study
- •Patients who have already been randomized in Protocol 303 at any center may not be considered for screening or for re-entry into the trial at any center, even after the end of their follow-up period
- •Patients with a history of poor compliance, or an unwillingness or inability to adhere to the requirements of the protocol.
Arms & Interventions
CHAM
Active Comparator
Cryopreserved Human Amniotic Membrane
Intervention: CHAM (Biological)
Control
Placebo Comparator
Standard of Care
Intervention: Control (Other)
Outcomes
Primary Outcomes
Complete closure of the index wound, defined as 100% re-epithelialization as determined by the Investigator, by the End of Single-Blind Treatment Visit with follow-up confirmation of continued closure at 2 consecutive study visits 2 weeks apart
Time Frame: Up to 112 days after Baseline Visit
Secondary Outcomes
- Complete index wound closure by the End of Single-Blind Treatment Visit as defined by 100% re-epithelialization, as determined by the Investigator.(Up to 84 days after Baseline Visit)
- Time to initial wound closure among patients that receive CHAM versus those that receive control as measured by Kaplan-Meier analysis.(Up to 84 days after Baseline Visit)
- Number of applications of CHAM versus control(Up to 77 days after Baseline)
- Percentage of patients who achieve complete wound closure, defined as 100% re-epithelialization as determined by the Investigator, who participate in the Open-Label Treatment Phase(Up to 91 days after Single-Blind Treatment Phase)
- Proportion of patients receiving CHAM that achieve a 50% reduction or greater in wound size by Day 28 (± 3 days) versus those that receive control.(Up to 28 days after Baseline)
Investigators
Study Sites (18)
Loading locations...
Similar Trials
Completed
Phase 4
Study Evaluating the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis SubjectsRheumatoid ArthritisNCT00252668Wyeth is now a wholly owned subsidiary of Pfizer300
Completed
Not Applicable
Study to Evaluate Safety and Efficacy of GrafixPL for the Treatment of Venous Leg UlcersVenous Leg UlcerNCT03629236Osiris Therapeutics200
Completed
Phase 3
A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual BleedingMenorrhagiaNCT01280981Ferring Pharmaceuticals288
Active, not recruiting
Not Applicable
Extension study to the multicenter, open-label, randomized, controlled study CRAD001H2304 to evaluate the long-term efficacy and safety of concentrationcontrolled everolimus in liver transplant recipients - NDliver transplantMedDRA version: 12.1Level: LLTClassification code 10024716Term: Liver transplantationEUCTR2009-017311-15-ITOVARTIS FARMA470
Active, not recruiting
Phase 1
A study conduct in several centres, further to a previous study, to evaluate the safety, tolerability and efficacy of ADV7103 at long term in the treatment of distal renal tubular acidosisDistal renal tubular acidosisMedDRA version: 20.1 Level: PT Classification code 10038535 Term: Renal tubular acidosis System Organ Class: 10038359 - Renal and urinary disordersEUCTR2013-003828-36-SKAdvicenne Pharma24